Page 5 - Pharma

Tax sops for craft paper, textile, pharma units in Madhya Pradesh

The Madhya Pradesh government is leaving no stone unturned to facilitate investment assistance to various sectors

Growth forecast in US market set to drive gains for Cipla stock

Street remains bullish on India prospects, regulatory headwinds for Goa site continue

Currency internationalisation: India pushes for rupee trade with Cuba

In July, the RBI had unveiled a mechanism to settle international transactions in rupee to promote the growth of global trade, with emphasis on exports from India

Discussion underway to extend PLI scheme to more sectors: Official

There are demands to extend production linked incentive (PLI) scheme to more sectors such as certain electronic components, pharma and medical devices, and discussions are underway in the government on these proposals, a senior government official said. Discussions are also going on to bring PLI scheme for toys, furniture, bicycles and containers. The objective of the scheme is to make domestic manufacturing globally competitive, create global champions in manufacturing, boost exports and create jobs. The government last year rolled out the scheme with an outlay of about Rs 2 lakh crore for as many as 14 sectors, including automobiles and auto components, white goods, textiles, advanced chemistry cell (ACC) and speciality steel. "So, from Rs 1.97 lakh crore, there are savings from some sectors. So against those savings, things are being planned. Proposals are under consideration," the official said. Demand for including sectors like certain electronic components, toys, furniture,

TMS Ep243: Ethical code for pharmas, EPFO, FMCG margins, moonlighting

Freebies to doctors: Why has the ethical code not been enforced? How has EPFO's equity investment experience been? Are FMCG companies eyeing better margins ahead? What is moonlighting? Answers here

India's rising medical devices imports hurt small and medium units

China accounts for about one-fifth of FY22 numbers; 41% surge overall

Draft Bill 2022 seeks to regulate e-pharmacies and medical devices

Centre also proposes to have an expert group on medical devices

Tax probe heat on Micro Labs, maker of India's go-to fever pill Dolo-650

During Covid-19, most patients were suffering from high temperatures, and the sales of this brand skyrocketed

Dolo-650 manufacturer faces raids by I-T dept in tax evasion case

A team of more than 20 officers associated with the I-T dept conducted the raids on the pharma company's Race Course Road office

Piramal Enterprises gets shareholders' nod to demerge pharma business

The company has received 99 per cent of votes at the shareholders meeting held on Tuesday, PEL said in a statement

Near-term outlook prescription for diagnostic firms looks fragile

Competitive pressures, high valuations limit upsides for listed lab chains

Analgesics, other common drugs used during Covid-19 clock double-digit CAGR

Pain and fever drug Paracetamol and blood-clot preventing Enoxaparin both post growth rates beyond 20%

PAG invests Rs 2,000 crore in Optimus Drugs for controlling stake

Exact stake size not revealed, sources put the number at 70%

Eyeing over 15% market share in US for insulin Glargine: Shreehas Tambe

The geopolitical incidents of the recent past as well as the pandemic have not really helped cost pressure: Tambe

Indian drug firms get a shot in the arm in $12-bn Australian drug market

India has over 750 USFDA approved plants and over 4000 products which are approved by either the US or EU or any other stringent regulator.

BS Awards for Corporate Excellence 2021: Samina Hamied lauds team effort

Cipla, which has seen a generational change in its leadership, draws 40 per cent of its revenues from India and 21 per cent from the US market.

MedisimVR raises Rs 3.5cr in pre-series A round led by IP Ventures

The funds raised by MedisimVR will be used by the company for scaling up its product offering and adding more skill training content to their library

Zydus unit to acquire brand from US-based BridgeBio Pharma

The agreement further adds to company's portfolio of medicines for rare and orphan diseases

Booster dose: India's pharma sector to grow at 6-8% YoY in FY23

India Ratings and Research (Ind-Ra) said it has maintained a neutral outlook for the Indian pharmaceutical sector for FY23.

Valuations turning attractive for Dr Reddy's as company outperforms sector

US price erosion, India growth trends would be keenly tracked